To better understand the clinical efficacy of selective HDAC6is combined with RT, we applied tubacin, a highly potent HDAC6i, to T24 cells and observed a repression of the RT-induced CXCL1 signalling pathway for cancer progression that was not present when applying panobinostat, suggesting a potential strategy of specifically targeting HDAC6 as a radiosensitizer for cancer treatment. Here, CXCL1 is linked to cancer.